- Home
- QNCX vs ONCY Comparison
QNCX vs ONCY Comparison
Compare QNCX & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QNCX
- ONCY
- Stock Information
- Founded
- QNCX 2012
- ONCY 1998
- Country
- QNCX United States
- ONCY Canada
- Employees
- QNCX N/A
- ONCY N/A
- Industry
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- ONCY Pharmaceuticals and Biotechnology
- Sector
- QNCX Health Care
- ONCY Health Care
- Exchange
- QNCX Nasdaq
- ONCY Nasdaq
- Market Cap
- QNCX 88.6M
- ONCY 89.7M
- IPO Year
- QNCX 2019
- ONCY 1999
- Fundamental
- Price
- QNCX $1.60
- ONCY $0.96
- Analyst Decision
- QNCX Strong Buy
- ONCY Strong Buy
- Analyst Count
- QNCX 6
- ONCY 5
- Target Price
- QNCX $8.00
- ONCY $5.00
- AVG Volume (30 Days)
- QNCX 271.4K
- ONCY 1.0M
- Earning Date
- QNCX 11-12-2025
- ONCY 11-07-2025
- Dividend Yield
- QNCX N/A
- ONCY N/A
- EPS Growth
- QNCX N/A
- ONCY N/A
- EPS
- QNCX N/A
- ONCY N/A
- Revenue
- QNCX N/A
- ONCY N/A
- Revenue This Year
- QNCX N/A
- ONCY N/A
- Revenue Next Year
- QNCX N/A
- ONCY N/A
- P/E Ratio
- QNCX N/A
- ONCY N/A
- Revenue Growth
- QNCX N/A
- ONCY N/A
- 52 Week Low
- QNCX $0.72
- ONCY $0.33
- 52 Week High
- QNCX $2.45
- ONCY $1.51
- Technical
- Relative Strength Index (RSI)
- QNCX 37.36
- ONCY 30.59
- Support Level
- QNCX $1.76
- ONCY $1.16
- Resistance Level
- QNCX $1.88
- ONCY $1.32
- Average True Range (ATR)
- QNCX 0.10
- ONCY 0.08
- MACD
- QNCX -0.03
- ONCY -0.02
- Stochastic Oscillator
- QNCX 9.28
- ONCY 11.22
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.
About ONCY Oncolytics Biotech Inc.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.